SCHEMBL19783111

SCHEMBL19783111

COC(=O)c1c(C)c(OC)cc2sc(N)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD2 Q8N5K1 8/20 0.46
CYP3A4 P08684 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
GRM6 O15303 1/20 0.40
GRM5 P41594 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19782968 0.85 CISD2 (0.41) CISD2MAPTKDM4EHDAC3HDAC4
SCHEMBL21395328 0.82 ALDH1A1 (0.41) CYP3A4MAPTKDM4EHSD17B10GRM6
SCHEMBL19782965 0.79 CYP3A4 (0.54) CYP3A4TDP1MAPTHSD17B10ALDH1A1
SCHEMBL642545 0.78 CYP3A4 (0.50) CYP3A4TDP1MAPTKDM4EHSD17B10
SCHEMBL9619834 0.76 HSD17B10 (0.55) CYP3A4MAPTKDM4EHSD17B10KCNH2
SCHEMBL19782621 0.76 CYP3A4 (0.50) CYP3A4TDP1MAPTKDM4EHSD17B10
SCHEMBL25942044 0.75 KDM4E (0.43) CYP3A4TDP1KDM4EHSD17B10KCNH2
SCHEMBL19782407 0.75 CYP3A4 (0.47) CYP3A4TDP1MAPTKDM4EHSD17B10
SCHEMBL30855901 0.75 ALDH1A1 (0.47) CYP3A4TDP1MAPTKDM4EHSD17B10
SCHEMBL6058096 0.73 HSD17B10 (0.55) CYP3A4MAPTKDM4EHSD17B10HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CISD2 4312/4885CYP3A4 15/4885TDP1 353/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CISD2 4469/4885CYP3A4 18/4885TDP1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.